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Risk-adapted partial larynx and/or carotid artery
sparing modulated radiation therapy of glottic
cancer
Stefan Janssen1, Christoph Glanzmann1, Gerhard Huber2 and Gabriela Studer1*
Abstract
Background: To evaluate outcome in patients with glottic cancer treated with intensity-modulated radiotherapy
(IMRT) and to show effectiveness of partial laryngeal- and/or carotid artery sparing in low to intermediate risk
tumors.
Study design: Retrospective analysis.
Material and methods: From 01/2004 to 03/2013 77 consecutive patients presenting with glottic cancer were
treated in our department with IMRT as definitive treatment. T-stages distributed as follows: T1: n = 17, T2: n = 24,
T3: n = 15, T4: n = 13 and recurrences: 8 patients. Concomitant systemic therapy was applied in 39 patients
consisting of either cisplatin or cetuximab.
Results: Mean/median follow-up (FU) time was 32.2/28 months (range: 4–98.7). Three year local control (LC),
ultimate LRC and laryngectomy free survival rate was 77%, 92% and 80%, respectively. Three year overall survival of
the entire cohort was 81%. Three year local control for T1/T2, T3/T4, and recurred tumors was 95%, 65%, and 38%,
respectively. Three year overall survival was 86% for T1-4 stages, 55% for recurred disease, respectively. Partial
laryngeal/carotid artery sparing was performed in all T1 patients (n = 17) and 17/22 T2N0 patients. Rate of late
sequels was low.
Conclusion: IMRT for glottic cancer shows high control rates. In low to intermediate risk tumors an individualized
treatment volume with partial larynx +/− carotid artery sparing is effective and holds the potential to reduce long
term toxicity. The therapeutic outcome was not compromised.
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Background
Glottic cancer is the most common laryngeal cancer and
no standard treatment has been established. Early glottic
cancer (T1-2 N0) is often treated with local radiotherapy
(RT) alone showing similar local control rates of 80-90%
compared to partial laryngectomy/laser resection [1].
Accelerated schedules of 63 Gy in 28 fractions 5 times a
week or 68/62 Gy in 34/32 fractions 6 times per week
seem to beneficial [2,3]. In advanced laryngeal cancer
larynx preservation is aimed with RT in combination
with systemic therapy (as induction and/or concomitant)
[4,5]. More advanced disease with consecutive laryngeal
dysfunction often requires a laryngectomy followed by
radio-/chemotherapy.
Against the background of the above mentioned excel-
lent control rates in early stage laryngeal cancer, chronic
sequels gain importance. Radiation-induced carotid artery
disease is long known [6]. In past years several series
reported on radiation-induced arteriosclerosis [7], stenosis
[8-11], and consecutive ischemic stroke [12-14]. In con-
ventional opposed fields the carotid arteries often receive
full dose. Intensity-modulated radiotherapy (IMRT) offers
the potential to spare surrounding tissues, e.g. carotid
arteries or parts of the larynx [15-21]. Latter series only
include few patients or consist of dosimetric comparison
of different treatment techniques only.
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We present control rates of the, to our knowledge, lar-
gest patient collective of laryngeal cancer patients treated
with carotid artery and/or partial larynx sparing IMRT in
low and intermediate stages.
Material and methods
Patients
From 01/2004 to 03/2013 77 consecutive patients present-
ing with glottic cancer were treated in our department with
IMRTas definitive treatment. Eight patients presented with
a local recurrence after trans-oral laser resection (10%). A
pretreatment panendoscopy and computed tomography
(CT) was carried out before treatment providing ana-
tomical information for delineation of the planning target
volume (PTV). Diagnosis was proven histologically in all
patients showing squamous cell carcinoma (SCC). Patient
and treatment related parameters are summarized in
Table 1. In six patients a tracheostomy was carried out
before RT start (8%).
Regular follow-up (FU) visits were carried out in our
joint clinic at the Department of Otorhinolaryngology,
Head and Neck Surgery. Institutional standards for
patient assessment included physical examination and
flexible fiber optic endoscopy approximately every
2 months in the first year of FU, every three months
in the second to third year and every 6 months in the
fourth to fifth year.
Analysis was approved by the ethics committee of the
Zurich university hospital.
IMRT/VMAT
We used simultaneously integrated boost (SIB) technique
in all patients. SIB-IMRT technique was performed using
the following schedules:
SIB2.00: 34–35 fractions with daily SIB doses of 2.00 Gy
(PTV1)/1.70 Gy (PTV2) and 1.54 Gy (PTV3) to a total
boost dose of 66.00-70.00 Gy (six/five fractions a week).
SIB2.11: 33 fractions with daily SIB doses of 2.11
(PTV1)/1.80 Gy (PTV 2) and 1.64 Gy (PTV3) to a total
boost dose of 69.60 Gy (five fractions a week).
The dose was normalized to the mean dose in PTV1.
For intensity optimization, the prescribed dose encom-
passed at least 95% of the PTV. Additionally, no more than
2% of any PTV received >110% of its prescribed dose.
Target volumes were delineated as follows: The primary
and involved lymph nodes included the gross extent of
disease, taking clinical and radiological findings into ac-
count; CTV was defined by adding 10-15 mm margin to
the GTV, another 2-3 mm margin was added from CTV
to PTV 1 dependent on proximity to critical structures;
PTV2 covered areas considered at high risk for potential
microscopic disease; and PTV3 included lymphatic path-
ways (elective PTV coverage). If possible we tried to spare
contralateral vocal cord and hypopharyngeal region from
high dose volume.
To ensure sufficient dose delivery to the skin close to
GTVs, bolus material (0.5-1 cm thickness) was used in
all patients with <5 mm between GTV and the overlying
skin as well as involvement of the anterior commissure
(n = 70, 91%). Hot spots in the arytenoid cartilage were
avoided.
Irradiation was delivered with four to five coplanar
beam angles by a 6-MV dynamic MLC system (Varian
Medical Systems, Palo Alto, CA) using sliding window
technique, or using volumetric modulated rapid arc
technique (VMAT, since 04/2010 (n = 13)). Patients were
immobilized from head to shoulders using a commer-
cially available thermoplastic mask in supine position.
Keeping the possibility of anatomical miss men-
tioned by Osman et al. in mind, good quality assurance is
Table 1 Patient and treatment related parameters
Gender
Male 68 (88%)
Female 9 (12%)
Mean age (years, range) 67 (35–87)
Mean gross primary tumor volume (pGTV, ml, range) 9.5 (0.2–88.7)
Planning target volume (PTV, ml, range)) 76.2 (18–283)
T-stage
T1 17 (22%)
T2 24 (31%)
T3 15 (20%)
T4 13 (17%)
Recurrence 8 (10%)
N-stage
N0 63 (79%)
N1 4 (5%)
N2a 0
N2b 5 (8%)
N2c 5 (8%)
N3 0
Concomitant systemic therapy 39 (51%)
Cisplatin 26 (34%)
Cetuximab 14 (18%)
Both (sequentially n = 2, simultaneously n = 1) 3 (4%)
RT prescription dose (total/single)
61.6/2.2 Gy 1 (1%)
63/2.25 Gy 2 (3%)
69.6/2.11 Gy 7 (9%)
66/2 Gy (6 f/week) 10 (13%)
68/2 Gy (6 f/week) 25 (32%)
70/2 Gy 32 (42%)
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mandatory [22]. We advise our patients not to swallow
during treatment. In addition daily kilovolt (KV) ima-
gines and regularly cone-beam computed tomographies
(CB-CT) (also to control the position of bolus material)
are carried out. Aberrations of more than 2 mm are cor-
rected before daily irradiation.
Treatment volumes
In T1 tumors and favorable T2 tumors without bulky
disease, no elective lymph node irradiation was carried
out (T1: 17/17, T2N0: 4/22). High dose planning treat-
ment volume was restricted to the involved area of the
larynx in order to spare contralateral laryngeal structures
and carotid artery (T1: in 15/17, T2N0: in 16/22, T3: in
10/15). In those patients carotid arteries were delineated
on planning CT on both sides (excluding patients with
elective node irradiation (ENI)).
Mean primary gross tumor volume (pGTV) was 9.5 ccm
(range: 0.2-88.7). Mean volume of planning target volume
(PTV) was 76.2 ccm (range: 18–283). For T1 tumors mean
GTV and PTV was 1.2 ccm (range: 0.2-3.5) and 40.9 ccm
(range: 18–92), for T2N0, the corresponding mean GTV
and PTV was 2.9 ccm (range: 0.7-7.6), and 55.7 ccm
(range: 35–123), respectively.
Systemic therapy
In case of recurrent tumor after laser resection, local
advanced T-stage, positive lymph nodes and bulky T2
tumors, systemic therapy was aimed. Systemic therapy
preferably consisted of cisplatin (40 mg/m2 weekly)
and was switched to cetuximab in case of cisplatin related
adverse effects (cetuximab loading dose: 400 mg/m2 fol-
lowed by weekly applications of 250 mg/m2). For patients
with contraindications against cisplatin, cetuximab was
favored primarily. Age, Karnofsky performance score and
comorbidities were respected.
In our study systemic therapy was carried out in 38 pa-
tients either with cisplatin (n = 21) or cetuximab (n = 14)
or combination of both (switch after cisplatin related side
effects (n = 2) or within a clinical trial applying concomi-
tant cisplatin and cetuximab (n = 1)). Cisplatin had to be
stopped due to pancytopenia after 1 (n = 1) or 3 courses
(n = 1), or due to rising level of creatinine after 2 (n = 1) or
3 courses (n = 1) or due to nausea after 2 (n = 1) or 4
courses (n = 1). Cetuximab had to be stopped due to re-
duction of general condition after 3 courses (n = 1) and
skin toxicity after 3 courses (n = 1).
Statistics
Statistical calculation was performed using the statistic
program implemented in StatView (Version 4.5; SAS In-
stitute, Cary, NC).
Results
Disease control
Mean/median follow-up was 32.2/28 months (range:
4–98.7). By the time of analysis 19 patients were dead
(25%). Three of them suffered from tumor progression, 10
died due to other causes (heart attack (n = 4), pneumonitis
(n = 1), stroke (n = 1), pulmonary embolism (n = 2), sepsis
(n = 1), progressive thyroid cancer (n = 1)). In the re-
maining 6 patients the cause of non-disease related death
is not known because they were lost in follow-up.
Four patients developed distant metastases (lung: (n = 4),
mediastinal lymph nodes (n = 1)). Two patients had
persistent nodal (and primary) disease; one patient
newly developed cervical lymph node metastases. In that
case a neck dissection was carried out in curative inten-
tion. We observed 13 local failures (including 2 patients
with persistent disease) (17%).
Radical laryngectomy was carried out as salvage therapy
in all 13 patients (after a mean time period of 11 months
after completion of RT (range: 3–18)). The 3 year ultimate
local-regional control rate was 92% (ultimate control: out-
come in patients with salvage surgery after local or nodal
failure included). Local control, nodal control and laryn-
gectomy free survival after 3 years was 77%, 93% and 80%,
respectively (Figure 1), overall survival was 81%. Local
control for T1/T2, T3/T4, and recurred tumors was 95%,
65%, and 38%, respectively. Overall survival was 86%
for T1-4 stages, 55% after IMRT of recurred disease,
respectively.
Partial larynx sparing
Partial larynx sparing IMRT was carried out in 43/
54 T1-3 N0 tumors (treatment volumes: Table 2). In two
T1N0 and one T2N0 partial larynx sparing was not pos-
sible due to tumor location close to the midline. In more
advanced tumors partial larynx sparing was not aimed.
Figure 1 Kaplan Meier curves for the entire study cohort.
DMFS = distant metastases free survival, NC: neck control, LC = local
control, DFS = disease free survival, OAS = overall survival.
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Carotid artery sparing
In all 17 T1N0 patients and four T2N0 patients bilat-
erally carotid sparing was performed. In cases of lymph
node metastases or ENI no carotid sparing could be
performed.
The mean dose to the ipsilateral contoured segment
of the carotid artery was 29.4 Gy (range: 1.1-72). The
mean dose to the contralateral carotid was 20.2 Gy
(range: 1–54.1). The mean volume receiving more than
35 Gy (V35), 50 Gy (V50) and 63 Gy (V63) was 30.1%,
Table 2 Simplified treatment volumes used in patients with T1-T4 laryngeal carcinomas
PTV1 (64–70 Gy) PTV2 (60 Gy) PTV3 (54 Gy)
T1 Affected laryngeal side (~1/2-2/3 of laryngeal volume) Small region above and below PTV1 –
T2 Affected laryngeal side (~2/3 of laryngeal volume) Small region above and below PTV1 Level II-V bilaterally (for small T2 tumors no ENI)
T3 Most of the larynx depending on tumor extension
(~3/4- 4/5 –entire laryngeal volume)
Small region above and below PTV1 Level II-V bilaterally
T4 Whole larynx Small region above and below PTV1 Level II-VI bilaterally
N+ Affected lymph node sites Small region around PTV1 Level II-VI bilaterally
ENI elective node irradiation.
Figure 2 Treatment plan of a patient with a T1N0 glottic carcinoma with high dose coverage of involved side only, red: larynx sparing
PTV1: 66 Gy, blue: PTV2 (60 Gy), yellow: carotid arteries.
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8.0% and 2.0% for the ipsilateral, and 7.1%, 0.5%, and 0%
for the contralateral carotid artery, respectively.
Tolerance
Rate of late sequels was low. 16 patients were in need
of a temporary gastric tube (21%, T1: n = 1, T2: n = 3,
T3: n = 3, T4: n = 8, recurrence: n = 1). One patient
(cT4c2b) developed a CTCAE grade 4 laryngeal edema
during the last week of radio-chemotherapy and was still
in need of a gastric tube at time of last FU visit (10 months
after therapy: alive and no evidence of disease). No other ≥
grade 3 adverse effects were observed.
Discussion
Radiotherapy is a major component in glottic cancer ther-
apy. In early stages it offers equal tumor control compared
to surgery. In advanced stages radio-chemotherapy holds
the chance for a conservative treatment approach in order
to avoid laryngectomy.
Figure 3 Example of treatment plan of a patient with a T3N0 glottic carcinoma, red: larynx sparing PTV1 (70 Gy), blue: PTV2 (60 Gy),
green: PTV3 (54 Gy), pink: GTV.
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We could show that partial larynx sparing and/or ca-
rotid artery sparing is feasible in most low to intermediate
risk glottic cancer patients without compromising tumor
control.
Larynx sparing IMRT
In advanced tumor stages it is recommended to include
the larynx generously in treatment volume. Additionally,
bilateral level II-IV lymph node regions are treated. In
the clinically node negative neck Eisbruch et al. advise to
include only the subdigastric nodes as upper border of
level II, for the clinically involved side the upper border
should reach the base of the skull reference. For stage
T2 the risk of lymph node metastases is borderline
[23-25]. In advanced T2 disease (with reduced vocal cord
mobility) elective irradiation of the neck (ENI) may be
indicated [26]. In our patient collective we included level
II-IV bilaterally in stage T2N0 disease by the majority.
Only small T2N0 tumors were treated without ENI
(n = 4/22). For small tumors we reduced the high dose
volume to the affected area in order to spare contralateral
laryngeal structures. This was realized in most T1-T3N0
tumors (43/54, Figures 2 and 3). Partial larynx sparing
is expected to reduce long term toxicity, which has
been shown low in our cohort. Haderlein et al. re-
cently stated that the dose to anatomical structures
responsible for swallowing function appears to play a role
in the treatment of laryngeal cancer [27]. Treatment
volumes for different tumor stages are summarized in
Table 2.
In recent years several study groups showed IMRT to
be effective in laryngeal cancer with comparable control
rates and improved tolerance compared to conventional
techniques ([28-32], see Table 3).
Table 3 IMRT studies in larynx tumors
Patients (n) Tumor stage Chemotherapy LRC OS
Eisbruch [30] 11 n.a. n. a. 60% (3 yrs) n. a.
Yao [29] 33 n.a. n. a. 85% (2 yrs) n. a.
Lee [31] 20 III/IV: 100% 100% 90% (2 yrs) 69% (2 yrs)
Studer [28]* 58 I/II: 31% 85% 65% (3 yrs) 78% (3 yrs)
II/IVA: 69%
Nguyen [32] 8 III/IVA: 100% 100% 85.2% (2 yrs) n. a.
Current study 77 I/II: 54% 28% 76% (3 yrs) 81% (3 yrs)
II/IVA: 46% 79%
LCR loco-regional control, OS overall survival, n. a. not applicable for laryngeal cancer exclusively.
*small number of patients included in both series.
Table 4 Carotid-sparing IMRT studies in early laryngeal cancer
Patients (n=) Tumor stage Prescription total/
single dose (Gy)
Objective Results
Rosenthal [20] 11 T1-2 N0 65/2.25 Comparison of opposed
lateral fields and IMRT
Best carotid-sparing with IMRT
Chera [15] 5 T1N0 63/2.25 Comparison of opposed
lateral field, 3D-RT and IMRT
Best carotid-sparing with IMRT
Sert [16] 5 T1N0 62.25/2.25 Comparison of opposed
lateral field, 3D-RT and IMRT
Best carotid-sparing with IMRT
(V35, V50, V63), identical conformity
Atalar [17] 5 T1N0 63/2.25 Comparison of conformal RT,
IMRT and IMAT
More hot spots in IMRT and IMAT,
less dose to carotids with IMRT/IMAT
Osman [21] 0 (comparative
planning in 10 cases)
T1N0 66/2 Comparison of conventional
plans and IMRT (coplanar and
non-coplanar)
Contralateral vocal cord sparing best
with single vocal cord RT IMRT
Mourad [19] 0 (comparative
planning in 1 case)
T1N0 63/2.25 Comparison of 2D, 3D and
IMRT plans in a patient with
complete left carotid artery
occlusion
Minimal dose to right carotid artery
and pharyngeal constrictor with IMRT
Riegel [18] 0 (comparative
planning in 11 cases)
T1-2 N0 63/2.25 Comparison of lateral opposed
fields, VMAT (full-arc, half arc)
and IMRT
Full-arc VMAT offers best carotid sparing
(and highest mean normal tissue dose),
static IMRT produced next-best carotid
sparing
IMRT intensity-modulated radiotherapy, IMAT intensity-modulated arc therapy, VMAT volumetric-modulated arc therapy.
Janssen et al. Radiation Oncology 2014, 9:136 Page 6 of 8
http://www.ro-journal.com/content/9/1/136
For early stage disease carotid sparing IMRT was
tested (mainly as comparative planning studies based on
small samples) few years ago by several investigators
(Table 4). In 2010 Rosenthal et al. from M.D. Anderson
Cancer Center revealed significantly reduced radiation
dose to the carotid arteries compared with conventional
lateral fields while maintaining target volume coverage
[20]. Other study groups showed similar results [21,33].
Chera and Feigenberg et al. challenge the interpretation
of a new standard because of the risk of complication
from dose heterogeneity [15,34].
To our knowledge the here presented series includes
the largest number of glottic tumor patients treated with
carotid sparing IMRT (n = 21) including a FU of mean/
median 32.2/28 years. The 3 years control rates are
comparable with historic series using conventional tech-
niques [35].
Carotid sparing IMRT
The risk of carotid artery stenosis after RT and conse-
cutive ischemic stroke is well known [7-14]. However,
there is no knowledge available regarding the influence
of the applied dose to the artery, length of irradiated
vessel, patients’ age or pre-existing vascular variances
on vascular changes. Especially in patients with long
life expectation after curative treatment this has to be
taken into account. Additionally patients with pre-existing
vascular risk factors (smoking history, diabetes, and hyper-
cholesterolemia) may benefit.
In early glottic cancer patients, we were able to keep
mean doses to carotid arteries below 25 Gy. Martin et al.
reported vessel wall abnormalities only at doses ≥35 Gy
or ≥50 Gy. In our patients with carotid sparing IMRT,
vessel volume receiving more than 35 Gy (V35) and V50
was below 20% and 5% of the contoured segments, re-
spectively [10]. Carotid artery sparing is principally known
realizable also with conventional radiation techniques, by
using IMRT this was found technically easily feasible in
most T1-2 patients. A clinical benefit could not be quan-
tified based on this study set up. As a limitation of the
present study one has to state that carotid sparing could
not be realized in patients with ENI.
Conclusion
Definitive partial larynx +/− carotid artery sparing IMRT
with highly conformal boost PTV is effective without
compromised control rates. A longer FU is needed to
strengthen the hypothesis of an improved therapeutic
ratio.
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